---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Neonatal fc receptor blockers"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Neonatal fc receptor blockers. Topics: FDA-approved neonatal Fc receptor blocker for CIDP: indication and dosing, Approval for CIDP, Subcutaneous efgartigimod randomized withdrawal trial: response and relapse, Open-label extension: long-term safety and function, and 4 further topics. 8 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/neonatal-fc-receptor-blockers"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Neonatal fc receptor blockers

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 Neonatal Fc Receptor Blockers

<a id="topic-2.2.2.1.6-1"></a>

### FDA-approved neonatal Fc receptor blocker for CIDP: indication and dosing

> “VYVGART HYTRULO is indicated for the treatment of adult patients with:”
> “The recommended dosage of VYVGART HYTRULO prefilled syringe is 1,000 mg / 10,000 units (1,000 mg efgartigimod alfa and 10,000 units hyaluronidase) administered subcutaneously over approximately 20 to 30 seconds as once weekly injections.”
> “The recommended dosage of VYVGART HYTRULO vial is 1,008 mg / 11,200 units (1,008 mg efgartigimod alfa and 11,200 units hyaluronidase) administered subcutaneously over approximately 30 seconds to 90 seconds as once weekly injections.”

Source: [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf)

<a id="topic-2.2.2.1.6-2"></a>

### Approval for CIDP

> “In June 2024, Vyvgart Hytrulo, marketed by argenx, was approved for the treatment of CIDP.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.2.2.1.6-3"></a>

### Subcutaneous efgartigimod randomized withdrawal trial: response and relapse

> “Participants with evidence of clinically meaningful deterioration entered an open-label phase of weekly 1000 mg subcutaneous efgartigimod PH20 for no longer than 12 weeks (stage A).”
> “Between April 15, 2020, and May 11, 2023, 629 participants were screened; 322 (114 female, 208 male) entered stage A, of whom 214 (66%, 95% CI 61·0-71·6) had confirmed ECI.”
> “Subcutaneous efgartigimod PH20 significantly reduced the risk of relapse versus placebo (hazard ratio 0·39 [95% CI 0·25-0·61]; p<0·0001). 31 (27·9% [19·6-36·3]) participants given subcutaneous efgartigimod PH20 had a relapse versus 59 (53·6% [44·3-63·0]) given placebo.”
> “In stage B, TEAEs occurred in 71 (64%) participants on subcutaneous efgartigimod PH20 and 62 (56%) participants on placebo, and serious TEAEs in six (5%) on subcutaneous efgartigimod PH20 and six (5%) on placebo.”

Source: [Allen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39304241/)

<a id="topic-2.2.2.1.6-4"></a>

### Open-label extension: long-term safety and function

> “At interim data cut‐off (February 16, 2024), 228/229 eligible participants advanced to ADHERE+.”
> “Prolonged efgartigimod exposure did not increase the incidence ( n = 171/228 [75.0%]) or severity of TEAEs (grade ≥ 3 TEAEs, n = 41/228 [18.0%]); regardless of immunoglobulin G level, there was a low incidence of infections.”
> “Stage A responders reported long‐term clinically meaningful improvements in mean aINCAT (decreased by 1.2 points), I‐RODS centile metric (increase of 8.8 points), and GS scores (increase of 17.5 kPa) from run‐in baseline to ADHERE+ week 36, irrespective of stage B treatment.”

Source: [Allen et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13375598/)

<a id="topic-2.2.2.1.6-5"></a>

### Subcutaneous efgartigimod randomized withdrawal trial: registry participant flow

> “population of treatment-naïve participants and participants who were previously treated for CIDP (corticosteroids, IVIg, or SCIg) with confirmed, active disease and a wide range of disease severity.”
> “A total of 322 participants received efgartigimod PH20 SC in Stage A, and 221 participants were randomized in a 1:1 ratio to efgartigimod PH20 SC (N=111) or placebo (N=110) in Stage B.”

Source: [ClinicalTrials.gov NCT04281472](https://clinicaltrials.gov/study/NCT04281472?tab=results)

<a id="topic-2.2.2.1.6-6"></a>

### Subcutaneous efgartigimod randomized withdrawal trial: registry results for stage B time-to-event and disability outcomes

| Stage B outcome | Efgartigimod PH20 SC | Placebo PH20 SC |
| --- | --- | --- |
| Median time to first adjusted INCAT deterioration, days (95% CI) | “NA[1] (NA to NA)” | “140.0[2] (75.0 to NA)” |
| Median time to CIDP disease progression, days (95% CI) | “NA[1] (247.0 to NA)” | “85 (50.0 to 253.0)” |
| Mean (SD) change in adjusted INCAT score from stage B baseline | “0.1(1.08)” | “0.9(1.98)” |

Source: [ClinicalTrials.gov NCT04281472](https://clinicaltrials.gov/study/NCT04281472?tab=results)

<a id="topic-2.2.2.1.6-7"></a>

### Subcutaneous efgartigimod randomized withdrawal trial: registry definitions for stage B outcomes

> “Insufficient number of participants with events, less than 50% of the participants had clinically deteriorated.”
> “Time to chronic inflammatory demyelinating polyneuropathy (CIDP) disease progression is defined by the time from first dose of double-blind IMP to the first I-RODS score decrease ≥4 points compared to Stage B baseline using the centile metric.”
> “Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) scores range from 0-10 with a score of 10 indicating the greatest degree of disability.”

Source: [ClinicalTrials.gov NCT04281472](https://clinicaltrials.gov/study/NCT04281472?tab=results)

<a id="topic-2.2.2.1.6-8"></a>

### Subcutaneous efgartigimod randomized withdrawal trial: registry all-cause mortality and serious adverse events

| Event | Stage A efgartigimod PH20 SC | Stage B efgartigimod PH20 SC | Stage B placebo PH20 SC |
| --- | --- | --- | --- |
| All-cause mortality, affected/at risk (%) | “2/322 (0.62%)” | “0/111 (0.00%)” | “1/110 (0.91%)” |
| Serious adverse events, affected/at risk (%) | “21/322 (6.52%)” | “6/111 (5.41%)” | “6/110 (5.45%)” |

Source: [ClinicalTrials.gov NCT04281472](https://clinicaltrials.gov/study/NCT04281472?tab=results)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
